Prab: CSV import

2025-02-15T11:05:31Z

CSV import

← Older revision		Revision as of 11:05, 15 February 2025
Line 1:		Line 1:
	~~'''~~Tavilermide''' is a [[pharmaceutical drug]] that was under development for the treatment of [[dry eye syndrome]]. It was developed by [[Mimetogen Pharmaceuticals]], a company based in [[Montreal]], Canada. The drug was designed to stimulate the production of [[mucin]], a key component of the tear film, in the eye's surface cells. However, the development of Tavilermide was discontinued in 2018.		{{DISPLAYTITLE:Tavilermide}}

	== ~~History~~ ==		==Overview==
			'''Tavilermide''' is a synthetic [[peptide]] that has been studied for its potential therapeutic effects in the treatment of [[dry eye syndrome]]. It is known to act as a [[nerve growth factor]] (NGF) mimetic, promoting the survival and maintenance of [[neurons]].

	~~Tavilermide was initially developed by Mimetogen Pharmaceuticals, a company that specializes in the development of small molecule drugs~~. ~~The drug was designed to stimulate the production~~ of ~~mucin in the eye's surface cells, which is a key component of the tear film. This was intended to help alleviate the symptoms of dry eye syndrome.~~		[[File:Tavilermide_structure.png\|thumb\|right\|Chemical structure of Tavilermide]]

	~~In 2013, Mimetogen entered into a licensing agreement with~~ [[~~Allergan~~]], a ~~global pharmaceutical company,~~ for the ~~development~~ and ~~commercialization~~ of Tavilermide~~. The drug entered Phase 3 clinical trials~~ in ~~2015~~.		==Mechanism of Action==
			Tavilermide functions by mimicking the activity of [[nerve growth factor]], a protein that is crucial for the growth, maintenance, and survival of certain target neurons. NGF binds to the [[TrkA receptor]], initiating a cascade of intracellular signaling that supports neuronal health. Tavilermide, by acting as an NGF mimetic, can potentially stimulate similar pathways, thereby offering therapeutic benefits in conditions where NGF activity is compromised.

	~~However, in 2018, Allergan announced that it was discontinuing the development~~ of Tavilermide~~. The decision was made following~~ the ~~results~~ of ~~two Phase 3 clinical trials~~, ~~which showed that~~ the ~~drug did not meet its primary endpoint~~ of ~~improving~~ the ~~signs~~ and symptoms ~~of dry eye syndrome~~.		==Clinical Applications==
			The primary clinical application of Tavilermide has been explored in the context of [[dry eye syndrome]], a condition characterized by insufficient lubrication and moisture on the surface of the [[eye]]. By promoting the health of [[corneal nerves]] and enhancing tear production, Tavilermide may alleviate symptoms associated with this condition.

	== ~~Mechanism of Action~~ ==		==Research and Development==
			Research into Tavilermide has focused on its efficacy and safety in treating [[ocular surface disorders]]. Clinical trials have been conducted to evaluate its potential benefits in improving tear production and reducing symptoms of dry eye syndrome. The outcomes of these studies are crucial for determining the viability of Tavilermide as a therapeutic agent.

	Tavilermide is a small molecule that mimics the action of [[nerve growth factor]] (NGF). It works by binding to the [[TrkA receptor]], which is found on the surface of cells in the eye. This stimulates the production of mucin, a key component of the tear film that helps to keep the eye moist.		==Potential Side Effects==
			As with any therapeutic agent, the use of Tavilermide may be associated with side effects. These can include local irritation at the site of application, transient [[blurred vision]], and other mild ocular symptoms. It is important for ongoing research to thoroughly assess the safety profile of Tavilermide.
	== ~~Clinical Trials~~ ==

	~~Tavilermide entered Phase 3 clinical trials in 2015. The trials were designed to evaluate~~ the ~~safety and efficacy~~ of ~~the drug in patients~~ with ~~dry eye syndrome~~. ~~However,~~ the ~~results~~ of ~~the trials showed that Tavilermide did not meet its primary endpoint of improving the signs~~ and symptoms ~~of dry eye syndrome~~.

	~~== Discontinuation ==~~

	~~In 2018, Allergan announced that it was discontinuing~~ the ~~development~~ of Tavilermide. ~~The decision was made following the results of two Phase 3 clinical trials. The company stated that it would continue to focus on its other ophthalmology products.~~

	~~== See Also ==~~

			==Related pages==
			* [[Nerve growth factor]]
	* [[Dry eye syndrome]]		* [[Dry eye syndrome]]
	* [[~~Mimetogen Pharmaceuticals~~]]		* [[Peptide]]
	* [[~~Allergan~~]]		* [[TrkA receptor]]
	* [[Clinical trial]]
	* [[Pharmaceutical drug]]

	~~{{stub}}~~

	[[Category:~~Pharmaceutical Drugs~~]]		[[Category:Peptides]]
	[[Category:Ophthalmology]]		[[Category:Ophthalmology]]
	[[Category:~~Clinical Trials]]~~		[[Category:Pharmacology]]
	~~[[Category:Discontinued Drugs~~]]

Prab: CSV import

2024-02-24T11:56:11Z

CSV import

New page

'''Tavilermide''' is a [[pharmaceutical drug]] that was under development for the treatment of [[dry eye syndrome]]. It was developed by [[Mimetogen Pharmaceuticals]], a company based in [[Montreal]], Canada. The drug was designed to stimulate the production of [[mucin]], a key component of the tear film, in the eye's surface cells. However, the development of Tavilermide was discontinued in 2018.

== History ==

Tavilermide was initially developed by Mimetogen Pharmaceuticals, a company that specializes in the development of small molecule drugs. The drug was designed to stimulate the production of mucin in the eye's surface cells, which is a key component of the tear film. This was intended to help alleviate the symptoms of dry eye syndrome.

In 2013, Mimetogen entered into a licensing agreement with [[Allergan]], a global pharmaceutical company, for the development and commercialization of Tavilermide. The drug entered Phase 3 clinical trials in 2015.

However, in 2018, Allergan announced that it was discontinuing the development of Tavilermide. The decision was made following the results of two Phase 3 clinical trials, which showed that the drug did not meet its primary endpoint of improving the signs and symptoms of dry eye syndrome.

== Mechanism of Action ==

Tavilermide is a small molecule that mimics the action of [[nerve growth factor]] (NGF). It works by binding to the [[TrkA receptor]], which is found on the surface of cells in the eye. This stimulates the production of mucin, a key component of the tear film that helps to keep the eye moist.

== Clinical Trials ==

Tavilermide entered Phase 3 clinical trials in 2015. The trials were designed to evaluate the safety and efficacy of the drug in patients with dry eye syndrome. However, the results of the trials showed that Tavilermide did not meet its primary endpoint of improving the signs and symptoms of dry eye syndrome.

== Discontinuation ==

In 2018, Allergan announced that it was discontinuing the development of Tavilermide. The decision was made following the results of two Phase 3 clinical trials. The company stated that it would continue to focus on its other ophthalmology products.

== See Also ==

* [[Dry eye syndrome]]
* [[Mimetogen Pharmaceuticals]]
* [[Allergan]]
* [[Clinical trial]]
* [[Pharmaceutical drug]]

{{stub}}

[[Category:Pharmaceutical Drugs]]
[[Category:Ophthalmology]]
[[Category:Clinical Trials]]
[[Category:Discontinued Drugs]]

Tavilermide - Revision history

Prab: CSV import

Prab: CSV import